Daily Cardiology Research Analysis
Today’s top cardiology papers include a large randomized trial showing intracardiac echocardiography is a noninferior and safer alternative to TEE before AF ablation, an integrated genomic model that combines polygenic, rare, and somatic drivers to improve AF risk prediction, and a phenomapping study in HFrEF that identifies three biologically distinct subgroups with markedly different outcomes and external validation.
Summary
Today’s top cardiology papers include a large randomized trial showing intracardiac echocardiography is a noninferior and safer alternative to TEE before AF ablation, an integrated genomic model that combines polygenic, rare, and somatic drivers to improve AF risk prediction, and a phenomapping study in HFrEF that identifies three biologically distinct subgroups with markedly different outcomes and external validation.
Research Themes
- Periprocedural imaging strategy for AF ablation
- Integrated genomic risk prediction for atrial fibrillation
- Data-driven phenomapping in HFrEF with multimodal biomarkers
Selected Articles
1. Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.
In 1810 AF ablation candidates randomized to ICE vs TEE for preprocedural thrombus screening, ICE was noninferior for thromboembolic events and reduced major bleeding from transseptal puncture. ICE also shortened fluoroscopy and waiting times and improved patient-reported anxiety/depression.
Impact: This pragmatic RCT directly informs a common pre-ablation workflow and demonstrates clinical, operational, and patient-experience benefits of ICE over TEE.
Clinical Implications: Programs can consider ICE as a first-line modality for thrombus screening before AF ablation, potentially reducing bleeding risk, radiation exposure, and procedural delays while improving patient comfort.
Key Findings
- ICE was noninferior to TEE for preventing periprocedural thromboembolic events (0.4% vs 0.6%; P for noninferiority = .01).
- Lower major bleeding related to transseptal puncture with ICE (0.2% vs 1.2%; RR 0.18).
- Operational advantages with ICE: reduced fluoroscopy time (4.2 vs 9.3 min) and preprocedural waiting time (14.4 vs 23.6 hours).
- Lower prevalence of anxiety/depression preprocedure with ICE (24.6% vs 37.5%).
Methodological Strengths
- Multicenter randomized noninferiority design with large sample size (n=1810).
- Registered trial with comprehensive clinical and patient-reported outcomes.
Limitations
- Short 30-day follow-up may miss later thromboembolic events.
- Blinding not feasible and event rates were low, potentially limiting power for rare outcomes.
Future Directions: Longer follow-up and cost-effectiveness analyses across diverse health systems could solidify guideline adoption and quantify resource implications.
IMPORTANCE: Transesophageal echocardiography (TEE) is the standard imaging modality for thrombus screening prior to atrial fibrillation (AF) ablation but carries procedural risks. Intracardiac echocardiography (ICE) is an alternative that may offer comparable safety with procedural advantages. OBJECTIVE: To determine whether ICE is noninferior to TEE in preventing periprocedural thromboembolic events in AF ablation. DESIGN, SETTING, AND PARTICIPANTS: This multicenter randomized clinical trial was conducted at 10 hospitals in China from August 2022 to July 2023, with a 30-day follow-up, enrolling adults with AF scheduled for catheter ablation who met predefined eligibility criteria. Data analysis was performed from August 2023 to December 2023. INTERVENTIONS: Thrombus screening with ICE or TEE prior to ablation. MAIN OUTCOMES AND MEASURES: The primary end point was the incidence of periprocedural thromboembolic events (stroke, transient ischemic attack, or systemic embolism). Secondary end points included thrombus detection, procedural safety and efficiency, and patient-reported comfort. RESULTS: A total of 1810 patients (mean [SD] age, 64.3 [9.4] years; 868 women [48.0%]; 887 patients [49.0%] with paroxysmal AF) were randomized to ICE (n = 906) or TEE (n = 904). Thromboembolic events occurred in 4 of 906 patients undergoing ICE (0.4%) and 5 of 904 patients undergoing TEE (0.6%) (risk difference, -0.11%; Farrington-Manning 95% CI, -0.84% to 0.62%; P for noninferiority = .01). Thrombus was detected in 2.0% vs 1.5% (relative risk [RR], 1.29; 95% CI, 0.64-2.61; P = .48) with ICE vs TEE, respectively, with more non-left atrial appendage thrombi in ICE (0.6% vs 0%; P < .001). Major bleeding related to transseptal puncture was lower with ICE (0.2% vs 1.2%; RR, 0.18; 95% CI, 0.04-0.81; P = .03). ICE reduced mean (SD) fluoroscopy time (4.2 [1.5] vs 9.3 [3.0] minutes; P < .001), preprocedural waiting time (14.4 [8.0] vs 23.6 [10.5] hours; P < .001), and anxiety or depression prevalence (24.6% vs 37.5%; RR, 0.66; 95% CI, 0.56-0.76; P < .001). CONCLUSIONS AND RELEVANCE: In this multicenter randomized clinical trial, ICE was noninferior to TEE for preventing thromboembolic complications in AF ablation and offered additional advantages in safety, efficiency, and patient comfort, supporting its use as a viable alternative in clinical practice. TRIAL REGISTRATION: ClinicalTrial.gov Identifier: NCT05466266.
2. Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation.
In 416,085 UK Biobank participants with whole-genome sequencing, polygenic risk, rare variant burden, and CHIP each independently associated with incident AF. Combining these genetic drivers and integrating with CHARGE-AF improved discrimination (C=0.80) and reclassification (NRI=0.08).
Impact: Provides an integrated genomic risk framework that complements clinical risk scores and supports precision screening strategies in AF.
Clinical Implications: Incorporating comprehensive genetic profiling (PRS, rare variants, CHIP) into AF risk assessment can refine identification of high-risk individuals beyond clinical factors and inform targeted prevention.
Key Findings
- Polygenic risk (per SD HR 1.65), rare variant gene set (HR 1.63), and CHIP (HR 1.26) independently predicted 5-year incident AF.
- Individuals with all three genetic drivers had at least 2-fold higher AF incidence than those with only one.
- Adding the integrated genomic model to CHARGE-AF improved C-statistic to 0.80 and NRI to 0.08.
Methodological Strengths
- Very large cohort with whole-genome sequencing and adjudicated AF outcomes.
- Integration of common, rare, and somatic variants with clinical risk and use of discrimination/reclassification metrics.
Limitations
- UK Biobank volunteer bias may limit generalizability; population predominantly of European ancestry.
- Incremental clinical utility, thresholds for action, and cost-effectiveness require prospective validation.
Future Directions: Prospective trials testing genomic risk–guided AF screening and prevention across diverse ancestries are warranted, along with health-economic analyses.
IMPORTANCE: Atrial fibrillation (AF) has a complex genetic architecture involving common, rare, and somatic variants. The association between these components requires further investigation. OBJECTIVE: To examine the individual and combined contributions of polygenic, monogenic, and somatic genetic variants to AF incidence, and develop an integrated genomic model (IGM-AF) for improved risk prediction. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used whole-genome sequence data from participants of the UK Biobank, with follow-up for AF events through hospital records, death registries, and self-report. The UK Biobank recruited participants aged 40 to 69 years in the UK between 2006 and 2010. Study data were analyzed from August 2022 to November 2024. EXPOSURES: IGM-AF comprising an AF polygenic risk score (PRS), a composite rare variant gene set (AFgeneset), and somatic variants associated with clonal hematopoiesis of indeterminate potential (CHIP). Clinical AF risk was estimated using the Cohorts for Heart and Aging Research in Genomic Epidemiology AF (CHARGE-AF) score. MAIN OUTCOMES AND MEASURES: The primary outcome was hazard ratios (HRs) for 5-year incident AF attributable to PRS, AFgeneset, CHIP, and their interactions. The predictive performance of IGM-AF and its components was quantified using HRs, C statistics, and reclassification indices. RESULTS: A total of 416 085 individuals (mean [SD] age, 56.6 [8.0] years; 224 642 female [54.0%]) with 30 797 AF cases were included. The PRS (HR per 1 SD, 1.65; 95% CI, 1.63-1.67; P < 1 × 10-8), AFgeneset (HR, 1.63; 95% CI, 1.52-1.75; P = 1.46 × 10-42), and CHIP (HR, 1.26; 95% CI, 1.15-1.38; P = 1.41 × 10-6) were associated with incident AF. The 5-year cumulative incidence of AF was at least 2-fold among individuals having all 3 genetic drivers (common, rare, and somatic drivers) compared with those with only 1 driver. Integration of IGM-AF with a clinical risk model (CHARGE-AF) showed higher predictive performance (C statistic, 0.80; 95% CI, 0.80-0.80) compared with IGM-AF and CHARGE-AF alone. The classification of the at-risk population for AF was improved when IGM-AF was added to CHARGE-AF (net reclassification index, 0.08; 95% CI, 0.07-0.09). CONCLUSIONS AND RELEVANCE: Results of this cohort study demonstrated the complementary value of common, rare, and somatic variants in shaping genomic AF risk. Leveraging comprehensive genetic information may enhance screening and preventive interventions for AF.
3. Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.
Using 105 multimodal variables, unsupervised clustering in VICTORIA identified three HFrEF phenogroups with stepwise risk for cardiovascular death or HF hospitalization and external validation in BIOSTAT-CHF. GDF-15 emerged as the top discriminator, highlighting biological underpinnings of residual risk.
Impact: Provides a reproducible, biology-informed stratification of HFrEF that can guide enrichment strategies and endpoint design in future trials targeting residual risk.
Clinical Implications: Phenotyping incorporating proteomics (e.g., GDF-15) may help identify HFrEF patients at highest residual risk and tailor follow-up intensity and therapeutic development.
Key Findings
- Three phenogroups were identified from 105 multimodal variables with distinct biology and risk profiles.
- Risk of cardiovascular death or HF hospitalization increased stepwise from phenogroup 1 to 3 (HR ~7.0 from 1 to 3).
- External validation in BIOSTAT-CHF supported generalizability; GDF-15 was the most important protein discriminator.
Methodological Strengths
- Multimodal integration (clinical, ECG, echo, biomarkers, targeted proteomics) and unsupervised clustering.
- External validation in an independent cohort (BIOSTAT-CHF).
Limitations
- Post hoc substudy with moderate sample size; observational clustering cannot infer causality.
- Proteomic panel was targeted; broader omics could reveal additional phenotypes.
Future Directions: Prospective validation and application of phenogroup-specific enrichment strategies in interventional HFrEF trials; exploration of mechanistic drivers and modifiable targets within high-risk phenogroups.
BACKGROUND: Patients with heart failure and reduced ejection fraction (HFrEF) have a high residual risk for heart failure hospitalizations and cardiovascular death. We aimed to use multimodality data to identify unique HFrEF subgroups with high residual risk. METHODS: In this VICTORIA substudy (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction), clinical, electrocardiographic, echocardiographic, quantitative biomarker, and targeted proteomics data were collected. Agglomerative hierarchical clustering was performed using 105 variables to define HFrEF phenogroups. Cox regression estimated the relationship between the HFrEF phenogroups and the primary composite outcome of cardiovascular death or heart failure hospitalization. External validation of the phenogroups was performed in the BIOSTAT-CHF cohort (Biology Study to Tailored Treatment in Chronic Heart Failure). Multinomial logistic regression identified the most important variables in defining the HFrEF phenogroups. RESULTS: There were 564 participants; after clustering, the optimal number of HFrEF phenogroups was 3. Phenogroup 1 was young, well-treated with guideline-directed medical therapy, and least likely to have an implantable cardioverter defibrillator. Phenogroup 2 had the highest prevalence of atrial fibrillation and pathological Q-waves on electrocardiography. Phenogroup 3 was older, had more biventricular dysfunction, and had advanced renal disease. A stepwise increase in risk of the primary composite outcome was observed from HFrEF phenogroup 1 to 3 (hazard ratio, 7.0 [95% CI, 4.1-12.0]; CONCLUSIONS: We identified and externally validated unique HFrEF subpopulations with shared biological characteristics that differentiated residual risk for cardiovascular death or heart failure hospitalization. GDF-15 was the most important protein used to distinguish the 3 HFrEF phenogroups. These findings may inform study entry criteria for future HFrEF trials focused on the development of novel therapeutics. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02861534.